Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Scientists have long considered ketones (a fundamental chemical class) and esters (molecules formed when an acid reacts with ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

The industry continues to face financial and regulatory headwinds, including high interest rates and uncertainty about ...

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Collectively, as well as independently, the firms represent generations of commercial real estate experience and family ...

This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

International Assets Investment Management LLC cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 98.4% ...